Oral booster probiotic bifidobacteria in SARS-COV-2 patients.
Int J Immunopathol Pharmacol
; 35: 20587384211059677, 2021.
Article
in English
| MEDLINE | ID: covidwho-1533223
ABSTRACT
Oral booster-single strain probiotic bifidobacteria could be a potential strategy for SARS-CoV-2. This study aims to evaluate the role of oral probiotic Bifidobacterium on moderate/severe SARS-CoV-2 inpatients. In this single-center study, we analyzed data of 44 moderate/severe inpatients with diagnosed COVID-19 in Istanbul Maltepe University Medical Faculty Hospital, 2020 from 1 November 2020 to 15 December 2020. Clinical and medication features were compared and analyzed between patients with or without probiotic. In result, 19 of the 44 patients (43.18%) who were administrated with oral booster-single strain probiotic were discharged with the median inpatient day of 7.6 days which were significantly shorter than those of patients without probiotic. There were significant differences in inpatient days, radiological improvement at day 6 and week 3, and reduction in interleukin-6 levels in those receiving oral probiotic therapy. Although the mortality rate was 5% in the probiotic group, it was 25% in the non-probiotic group. Booster-single strain probiotic bifidobacteria could be an effective treatment strategy for moderate/severe SARS-CoV-2 inpatients to reduce the mortality and length of stay in hospital.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Bifidobacterium
/
Interleukin-6
/
Probiotics
/
COVID-19
/
COVID-19 Drug Treatment
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Female
/
Humans
/
Male
/
Middle aged
Country/Region as subject:
Asia
Language:
English
Journal:
Int J Immunopathol Pharmacol
Journal subject:
Allergy and Immunology
/
Pharmacology
/
Pathology
Year:
2021
Document Type:
Article
Affiliation country:
20587384211059677
Similar
MEDLINE
...
LILACS
LIS